search for


Use of Anti-vascular Endothelial Growth Factors for Diabetic Retnopathy: National Health Insurance Claims Data
당뇨망막병증에서 항혈관내피성장인자의 국내 사용 현황: 국민건강보험공단 자료 분석
JKOS 2019 Jul;60(7):661-6
Published online July 15, 2019;
Copyright © 2019 The Korean Ophthalmological Society.
PDF Download Count: 83 / View Count: 102

Songhee Cho, MS1, Sang Jin Shin, PhD1, Jae Kyung Suh, PhD1, Hajin Tchoe, MS1, Jangmi Yang, MS1, Min Joo Kang, MS1, Donghyun Jee, MD, PhD, MPH2

Office of Economic Evaluation Research, National Evidence Based Health Care Collaborating Agency1, Seoul, Korea
Department of Ophthalmology and Visual Science, St. Vincent Hospital, College of Medicine, The Catholic University of Korea2, Seoul, Korea
한국보건의료연구원 경제성평가연구팀1, 가톨릭대학교 의과대학 성빈센트병원 안과 및 시과학교실2
Received May 3, 2018; Revised July 19, 2018; Accepted June 19, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose: To evaluate the current use of intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in patients with diabetic retinopathy.
Methods: We determined the current number of diabetic retinopathy patients and their medical expenditure using National Health Insurance Service claims data (2007-2016). We also analyzed the medical costs of patients with diabetic retinopathy who received anti-VEGF treatment, including ranibizumab and aflibercept. We then evaluated aspects of the use of anti-VEGF injections, such as frequency and intervals, in newly diagnosed diabetic retinopathy patients who received anti-VEGF treatment, along with their medical costs.
Results: The number of patients with diabetic retinopathy was 397,956 in 2009 and 721,310 in 2016, a 1.8-fold increase over 8 years. Of these, the number of patients undergoing anti-VEGF therapy was 4,283 in 2015 and 4,270 in 2016. Of the diabetic retinopathy patients in 2016, the total medical cost of those treated with anti-VEGF was 1.5 billion won, and the average medical cost per person was 3,531,064 won.
Conclusions: Based on the National Health Insurance claims data, the use of ranibizumab and aflibercept is increasing. The results of this study suggest that diabetic retinopathy will become an important public health issue.
Keywords : Aflibercept, Anti-vascular endothelial growth factor, Diabetic retinopathy, Ranibizumab


November 2019, 60 (11)